CReST showed that stenting as a bridge to surgery reduces stoma formation without detrimental effects in colon cancer patients with left-sided colonic obstruction #ICTD2023@BJSurgerytinyurl.com/2p9uh8s8
Recruiting from 80 hospitals in 7 global south countries, @CheetahRct found that 1 in 8 surgical site infections could be prevented by changing gloves and instruments before fascial closure for abdominal surgery @TheLancet@NIHR_GSU#ICTD2023tinyurl.com/4p32e4p3
The @STOPACEi_trial showed that in people with advanced and progressive chronic kidney disease, discontinuation of RAS inhibitors was not associated with difference in rate of decrease in kidney function measured using eGFR @NEJM#ICTD2023tinyurl.com/42whfnwd
Jointly delivered with @CRCTU the MSc in Clinical Trials provides a foundation to clinical trials covering theoretical & practical aspects of the design, conduct, analysis and interpretation of trials. Developed for a broad audience from industry, NHS Trusts & academia #ICTD2023
Published in @JCO_ASCO, FOxTROT showed that six weeks of preoperative chemotherapy for operable colon cancer can be delivered safely and provides better 2-year disease control #ICTD2023tinyurl.com/4mmmm5sj
BCTU, a UKCRC registered trials unit was 25 years old in 2022. Clinical Trial Units play a key role in the design and delivery of clinical trials. To celebrate #ClinicalTrialsDay we will be tweeting about some of the trials we have delivered over the past 12 months.
ALT Birmingham Clinical Trial Unit's 25th birthday celebrations in 2022.
Proud beyond words of the work of colleagues from @unibirmingham
@unibirm_MDS @IMSR_UoB @UoB_IAHR Partnering with the @WHO and @gatesfoundation , implementation of the intervention would have huge impact .
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)
#crcsmascopubs.org/doi/full/10.120…
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)
#crcsmascopubs.org/doi/full/10.120…
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)
#crcsmascopubs.org/doi/full/10.120…
📢 News: FOxTROT, a trial we funded, has shown that starting chemotherapy before surgery, instead of after, can significantly cut the risk of colon cancer coming back. The findings could change how doctors treat colon cancer in the NHS and around the world bit.ly/3iUSRnd
FOxTROT-1 trial results have been released by @JCO_ASCO!
✅Pre-operative chemotherapy for locally advanced operable colon cancer is safe
✅Improved histopathological & oncological outcomes
✅Reduced 2-year recurrence
ascopubs.org/doi/10.1200/JCO…
But that's not all! FOxTROT-2 and 3 are currently active and further researching neoadjuvant chemotherapy in colon cancer. You can find out more at @FoxtrotStudy@LeedsCTRU
Our trials WILL, iHOLDS, Giant PANDA and CAPE are all being exhibited at the BCTU stand at #BMFMS at Birmingham's Millennium Point today. Come and speak to the teams for more information on these exciting trials #clinicaltrials#WomensHealth